Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 2 Prostatic Neoplasms 1 HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Advanced Gastric Cancer 1

Interventions

Bevacizumab 47 lenvatinib 36 atezolizumab 36 durvalumab 28 tremelimumab 23 sintilimab 19 Nivolumab 18 pembrolizumab 14 Radiosurgery 13 tislelizumab 11 Specimen Handling 10 Ipilimumab 10 camrelizumab 8 apatinib 8 Oxaliplatin 8 Immune Checkpoint Inhibitors 8 Fluorouracil 8 Cyclophosphamide 8 Blood Specimen Collection 8 regorafenib 7 cabozantinib 7 fludarabine 6 Sorafenib 6 Radiotherapy 6 Magnetic Resonance Spectroscopy 6 Leucovorin 6 donafenib 5 Surgical Procedures, Operative 5 Injections 5 Immunoglobulin G 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Carcinoma, Hepatocellular × SHR-1701 × Clear all

NCT06893887 2025-07-02

ICT-HCC

Nanjing Tianyinshan Hospital

Phase NA Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡